Explore Topics

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

An interview with Matt George, patient advocate and survivor of paroxysmal nocturnal haemoglobinuria (PNH), a debilitating, rare and life-threatening disorder.

Demonstrate the value of rare disease therapies with these five key ways to connect where patients, physicians and payers perceive the most value.

The five components manufacturers shouldn't ignore when building orphan drug support programs.